[custom_product_image id="197"]
Purity
99.79%
Batch ID
DXP-RETA-2601
Format
Lyophilised
For research use only
Retatrutide 10 mg
Price range: $75.00 through $185.00
The "Triple G" action — one molecule, three pathways
In stock · dispatched today
[custom_bulk_pricing product_id="197"]
5% OFF
Discount Applied
$330.00
→
$313.50
Save $16.50
- Free express post on orders over $100
- Sealed under nitrogen for long-term stability
- Independent HPLC-MS certificate on this batch
Frequently Bought Together
Loading products...
Bundle total
(0 items)
$0.00
What is Retatrutide?
A next-generation incretin agonist that simultaneously activates three key pathways — GIP, GLP-1 and glucagon — to help regulate appetite, improve metabolic function, and increase energy expenditure.
Key mechanism
One molecule. Three powerful pathways. Greater metabolic impact.
- GIP — glucose-dependent insulinotropic polypeptide: insulin secretion, nutrient utilisation, fat storage
- GLP-1 — glucagon-like peptide-1: appetite, satiety, food intake
- Glucagon: energy expenditure, fat oxidation, supports weight loss
Clinical trial results
Significant weight loss. Broader metabolic benefits.
In the Phase 2 TRIUMPH-1 trial, retatrutide demonstrated dose-dependent reductions in body weight over 48 weeks: -1.6% placebo, -8.7% at 1 mg, -16.3% at 4 mg and -24.2% at 8 mg (mean baseline weight ~107 kg).
- 91% achieved ≥ 5% weight loss (8 mg, 48 weeks)
- 75% achieved ≥ 10% weight loss
- 55% achieved ≥ 20% weight loss
- Cardiometabolic markers: triglycerides -24%, LDL cholesterol -17%, HbA1c -7%
Key research highlights
- Triple agonist: GIP + GLP-1 + glucagon
- Supports appetite control and calorie burn in research
- Dose-dependent results across 48 weeks in Phase 2
- Improvements in key cardiometabolic markers
Source: Jastreboff AM, et al. N Engl J Med. 2023 (TRIUMPH-1 Phase 2 Trial). Retatrutide is an investigational compound and not approved for clinical use.